Aktis Oncology, Inc. · NASDAQ:AKTS

Aktis Oncology — Jefferies Global Healthcare Conference 2026

21 slides from Aktis Oncology's conference presentation, June 2026

1. Slide 1: Radiopharmaceuticals reimagined to redefine cancer care

   Radiopharmaceuticals reimagined to redefine cancer care Jefferies Global Healthcare Conference June 2026 1

2. Slide 2: Disclaimer

   Disclaimer Information in this presentation and the accompanying oral presentation contains forward-looking statements within the meaning of the Private Securities Litigation Act of 1995 that involve substantial risks and uncertainties about Aktis Oncology and the industry in which Aktis Oncology op

3. Slide 3: Aktis is positioned to lead the next generation of targeted radiopharmaceuticals

   Aktis is positioned to lead the next generation of targeted radiopharmaceuticals Novel and Differentiated Platform Two Clinical Programs Accomplished Addressing Large Market Leadership Team Tumor Types Strong Imaging Proof-of- Balance Sheet Concept in Patients Pillars of value Isotope Supply Pipelin

4. Slide 4: Focused on targets that enable expansion to broad populations with significant unmet needs

   Focused on targets that enable expansion to broad populations with significant unmet needs TOTAL INCIDENCE, METASTATIC SOLID TUMORS RADIOPHARMACEUTICAL TARGETS TODAY Bladder 1% 1% Sarcoma PSMA SSTR2 Melanoma Brain* <1% Liver Esopheageal 3% 2% 3% Up to Up to Stomach 3% 24K 38K Ovarian 4% addressed ad

5. Slide 5: Patient-centric approach to maximizing radiopharmaceutical impact

   Patient-centric approach to maximizing radiopharmaceutical impact GOAL TO MAXIMIZE PATIENT BENEFIT DESIGNED TO EXPAND RADIOPHARMACEUTICAL IMPACT Isotope-agnostic to Drive efficacy image and treat Non-cleavable linker Widen safety window Folded miniprotein target binder (~40-60aa) Address more target

6. Slide 6: Aktis is advancing a novel pipeline for large patient populations

   Aktis is advancing a novel pipeline for large patient populations PROGRAM TARGET/INDICATION DISCOVERY IND-ENABLING PHASE 1b PHASE 2/3 UPCOMING MILESTONES Nectin-4 expressing Ph1b ongoing AKY-1189 Fast Track Designation* solid tumors Prelim data in 1Q’27 B7-H3 expressing Ph1b initiated mCRPC Prelim d

7. Slide 7: Lead programs present potential megablockbuster opportunities

   Lead programs present potential megablockbuster opportunities Initial addressable patient populations Forecasted worldwide peak sales4 Metastatic Nectin-4 B7-H3 Initial Indication incidence expression expression in US1 Positioning positive2 positive3 $5.4 Billion Locally advanced ~4.2k 2L 86% -- or

8. Slide 8: Enabling clinical supply for large populations through resilient and scalable network

   Enabling clinical supply for large populations through resilient and scalable network Miniprotein manufacturing Experienced GMP solid-phase peptide Drug product Patient manufacturing partners administration Distribution Manufacturing Quality Unit dose control release Multiple distributors White glov

9. Slide 9: AKY-1189: Nectin-4 Program

   AKY-1189: Nectin-4 Program

10. Slide 10: Clinical imaging supports potential of AKY-1189 for the treatment of Nectin-4 expressing tumors

    Clinical imaging supports potential of AKY-1189 for the treatment of Nectin-4 expressing tumors with a wide therapeutic window Favorable normal tissue uptake compared to approved RLTs* Rapidly cleared from kidney and bone marrow Predicted absorbed Kidneys AKY-11891 Pluvicto 2 Lutathera®3 Bone Marrow

11. Slide 11: Treatment opportunities in urothelial cancer and beyond

    Treatment opportunities in urothelial cancer and beyond Urothelial Cancer ER/PR+ mBC Triple Negative Breast Cancer Colorectal Cancer 60 min 60 min 60 min 60 min [68Ga]Ga-AKY-1189 PET/CT • Robust tumor uptake observed in high unmet need tumor types with SUVmax 20-40 • Consistent normal tissue distrib

12. Slide 12: Phase-1b trial actively enrolling patients at US clinical trial sites across multiple Nectin-4 expressing tumors

    Phase-1b trial actively enrolling patients at 11 US clinical trial sites across multiple Nectin-4 expressing tumors NECTINIUM-2 Trial design PART 1 PART 2 Dose escalation BOIN, mUC + Nectin-4+ patients Dose Expansion, multiple tumor types (n=~30 + backfill) (n=30-40 per cohort) Expansion cohorts 12

13. Slide 13: AKY-2519: B7-H3 Program

    AKY-2519: B7-H3 Program

14. Slide 14: AKY-2519 demonstrates robust tumor uptake and retention with wide therapeutic index

    AKY-2519 demonstrates robust tumor uptake and retention with predicted absorbed doses suggesting a wide therapeutic index A PET/CT B SPECT/CT E % COVERAGE F Mean Absorbed Dose Predicted Dose1 SECT/CT AXIAL IMAGES AT 24 HOURS Region of Interest Coefficient (225Ac) at 8 MBq x 4 GyRBE=5/MBq GyRBE=5 Inv

15. Slide 15: Clinical imaging and dosimetry data in patients with mCRPC suggest a wide therapeutic index

    Clinical imaging and dosimetry data in patients with mCRPC suggest a wide therapeutic index and informed the Phase 1b trial design Normal tissue doses were below Robust tumor uptake and retention with predicted absorbed established clinical benchmarks doses suggesting a wide therapeutic index Mean A

16. Slide 16: [68Ga]Ga-AKY-2519 demonstrates robust tumor uptake in a variety of solid tumors

    [68Ga]Ga-AKY-2519 demonstrates robust tumor uptake in a variety of solid tumors Representative patients across solid tumor types with robust tumor uptake at 120 minutes following [68Ga]Ga-AKY-2519 administration • Uptake of [68Ga]Ga-AKY- 2519 was observed across multiple tumor types at various time

17. Slide 17: Ongoing mCRPC-dedicated Phase 1b trial in PLUVICTO-naïve and -experienced patients

    Ongoing mCRPC-dedicated Phase 1b trial designed to rapidly generate data in PLUVICTO-naïve and -experienced patients BActinium-1 Trial design Dose escalation: BOIN Backfill (n ≈ 30/cohort; escalation pts included) 12 MBq THERAPY THERAPY Backfill Dose 1 PLUVICTO-naïve [225Ac]Ac-AKY-2519 [225Ac]Ac-AKY

18. Slide 18: On track to initiate Phase 1b AKY-2519 basket trial in 2H'26

    On track to initiate Phase 1b AKY-2519 basket trial in 2H’26 BActinium-2 Trial design PART 1 PART 2 Dose escalation: BOIN (n = up to 18) Backfill (n = up to 60) Dose expansion (n = up to 70) 12 MBq BACKFILL 2L(+) NSCLC THERAPY Cohort 1 Dose 1 [225Ac]Ac-AKY-2519 2L(+) NSCLC THERAPY 2L(+) Other (n=31)

19. Slide 19: Upcoming milestones

    Upcoming milestones

20. Slide 20: Recent and anticipated milestones over the next 12 months

    Recent and anticipated milestones over the next 12 months AKY-1189 (Nectin-4) AKY-2519 (B7-H3) Corporate 1Q’26: Granted Fast Track 1Q’26: Received IND 2H’26: Aktis GMP designation in locally clearance manufacturing suite advanced or mUC operational 2Q’26: mCRPC Ph1b trial start 1Q’27: Preliminary da

21. Slide 21: Thank You

    Thank You — =

Aktis Oncology — Jefferies Global Healthcare Conference 2026 on 6ix